Title
PHASE II STUDY OF IBERDOMIDE (CC220) MAINTENANCE AFTER AUTOLOGOUS STEM CELL TRANSPLANTION IN NEWLY DIAGNOSED MULTIPLE MYELOMAStudy map
Overview / Summary
Study details
The study is sponsored by EMN Foundation and focuses on maintenance during first line of therapy.
Patient eligibility criteria
Newly diagnosed multiple myeloma (NDMM) patients in at least partial response (PR) after induction with proteasome inhibitors (PIs) plus IMIDs and single or double ASCT
